- Kiyosaki Uncensored
- Posts
- Microsoft, Google, and NVIDIA Are Betting on AI in Healthcare. Should You?
Microsoft, Google, and NVIDIA Are Betting on AI in Healthcare. Should You?
Disseminated on behalf of Light AI Inc. Please Read Disclosures
(OHCFF.USOTC)
Dear Reader,
In Silicon Valley, there’s an old saying: "Follow the money." And in 2024, the money is headed straight into one of the most explosive sectors in the market—
Healthcare AI.
It’s not just hype. Big Tech is going all-in:
Microsoft deepened its partnership with NVIDIA, merging Azure with NVIDIA's DGX Cloud and Clara suite to accelerate medical imaging and clinical diagnostics [xvi].
Google has rolled out generative AI features for doctors and clinicians, helping them pull clinical insights faster and more accurately [iv].
The global market for AI diagnostics is on track to hit $12.65 billion by 2034, growing at an astonishing 24.64% CAGR [x] .
In other words, the future of medicine isn’t just about new pills or surgical robots—it’s about software that thinks.
And right now, one under-the-radar company is carving out a unique space in this revolution: Light AI Inc. (OHCFF.USOTC).
What’s Driving the Billion-Dollar Rush into Healthcare AI?
Let’s look at the fundamentals. The U.S. healthcare system is under more pressure than ever:
Labor costs are up 37% since 2019 [v] .
Administrative costs swallow 25% of America’s $4.3 trillion healthcare spend annually [v] .
We’re hurtling toward a projected shortage of 86,000 physicians by 2036 [xv] .
And that’s before we even talk about the growing risk of superbugs and global pandemics.
Now factor in this: in clinical studies, AI diagnostic tools are already beating human doctors.
A 2023 Stanford University study showed AI tools diagnosing illness with 92% accuracy, while doctors averaged 74% [vii] . Another JAMA-published analysis confirmed these findings—AI chatbots outperformed physicians in diagnostic accuracy [xiv] .
This is no longer theoretical. AI is proving it can save lives—and dollars.
Which brings us back to Light AI.
Why Light AI May Have Found the Sweet Spot
Light AI isn’t trying to build the next CT scanner or electronic health record system. They’ve done something more elegant—and potentially more powerful.
They created a smartphone-based diagnostic system, powered by artificial intelligence, that can identify Strep A infections in just 45 seconds, with 96.57% accuracy. [i]
It works without a lab. Without special equipment. All it needs is the one device most of the world already owns: a smartphone.
That simplicity opens the door to scale quickly—both in the U.S. and globally.
They’ve already:
Raised over $18 million
Built a database of 300,000+ clinical images
Achieved clinical-grade performance
Secured multiple patents across the U.S., EU, Canada, Australia, and Israel [i]
And their leadership team? It’s stacked with veterans of Johnson & Johnson, Bristol Myers Squibb, Medtronic, and global venture capital firms.
Let’s Talk About the People Behind the Tech
Behind every great innovation is a team bold enough to take the leap—and smart enough to pull it off.
Here’s who’s steering Light AI:
Peter Whitehead, Founder & CEO – Best known for inventing the VELScope, a market-leading oral cancer detection tool that changed how doctors screen for cancer worldwide.
Steve Semmelmayer, Chairman – Former CEO of Discus Dental and Denmat Holdings, with 37 years of dental and medical experience.
Thomas Scarnecchia, COO – Former tech executive at Johnson & Johnson R&D, with deep experience leading AI and computational science teams.
Their board includes:
Hugh Cleland (Harvard, CFA), co-founder of Roadmap Capital and recipient of the "Opportunities Strategy Hedge Fund Award"
Mark Attanasio, a Canadian venture capital veteran and former CEO of Eight Capital
Emmanuel Blin, former Chief Strategy Officer of Bristol Myers Squibb, now CEO of Light AI’s strategic partner TC4A
The advisory board is equally stacked, including:
Dr. Raymond Ng, PhD in AI and Director of UBC’s Data Science Institute
Dr. David Bell, former WHO coordinator for malaria diagnostics
Dr. David Talan, CDC principal investigator and top infectious disease expert
Yu Zhao, Medtronic veteran with deep FDA regulatory experience
Put simply, this is a company that didn’t cut corners. They built it right—from day one.
The Investment Landscape Is Shifting
Here’s what’s most interesting: investors are starting to catch on.
Since 2021, 60% of AI health startup funding has gone to companies solving administrative and diagnostic problems—just like Light AI [xiii] .
That investment has now hit a projected $11.1 billion in 2024 alone, marking the biggest surge since the pandemic [xiii] .
Meanwhile, healthcare companies leveraging AI are being valued at up to 5x higher than their traditional counterparts [vii] .
That’s the smart money talking.
Why This Matters Right Now
We’re standing at the crossroads of a global healthcare shift. AI is no longer a curiosity—it’s becoming the backbone of modern medicine.
Light AI’s timing couldn’t be better:
Their product is ready.
Their patents are secured.
Their markets—LMICs, U.S. healthcare, and wellness—are already in motion.
And Big Tech is laying the infrastructure that Light AI could ride into mass adoption.
This isn’t a guarantee. No investment is. But it has all the hallmarks of a company that could be at the front of one of the most important transformations in modern healthcare.
Put Light AI (OHCFF.USOTC) on your watchlist today.
Kiyosaki Research
References
i LightAI Investor Presentation
ii "Superbugs could jeopardise food security for over two billion people", WOAH
iii "Antimicrobial Resistance (AMR)", World Bank
iv "AI in Healthcare Market Size, Share & Industry Analysis", Fortune Business Insights
v "The Potential Financial Benefits of AI in Healthcare Organizations", InfoTech
vi "Ten threats to global health in 2019", World Health Organization
vii "AI Medical Tools Show Promise as Health Tech Markets Rally", PYMNTS
viii "Artificial Intelligence in Diagnostics Market Size to Hit USD 8.54 Bn by 2033", BioSpace
ix “Category Design for Entrepreneurs: How to Become a Category King”, Category Pirates
x "AI in Diagnostics Market Size Skyrockets by 24.64% CAGR by 2034", Globe Newswire
xi "Artificial intelligence could save healthcare industry $360B a year", Healthcare Dive
xii "HealthTech Startups Valuation: Methods, Challenges and AI Adoption", Finrofca
xiii "2024 shaping up to be a big year for healthcare AI companies", Fierce Healthcare
xiv "A.I. Chatbots Defeated Doctors at Diagnosing Illness", New York Times
xv “New AAMC Report Shows Continuing Projected Physician Shortage”, AAMC
xvi "Artificial Intelligence in Medical Diagnostics Market to Hit USD 4.72 Billion by 2029", Yahoo Finance
IMPORTANT DISCLAIMER & DISCLOSURES
Investing in stocks is HIGH RISK. You could lose all of your investment.
Freedom Financial Research, as a publisher, is not a broker, investment advisor, or financial advisor in any jurisdiction.
Please do not rely on the information presented by Freedom Financial Research as personal investment advice.
If you need personal investment advice, kindly reach out to a qualified and registered broker, investment advisor, or financial advisor.
The communications from Freedom Financial Research should not form the basis of your investment decisions. Examples we provide regarding share price increases related to specific companies are based on randomly selected time periods and should not be taken as an indicator or predictor of future stock prices for those companies.
Light AI Inc. is a paid sponsor of this report.
The information in this newsletter does not constitute an offer to sell or a solicitation of an offer to buy any securities of a corporation or entity, including U.S. Traded Securities or U.S. Quoted Securities, in the United States or to U.S. Persons. Securities may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and applicable U.S. state securities laws or pursuant to an exemption therefrom.
Any public offering of securities in the United States may only be made by means of a prospectus containing detailed information about the corporation or entity and its management as well as financial statements. No securities regulatory authority in the United States has either approved or disapproved of the contents of any newsletter. Freedom Financial Research nor any employee of Freedom Financial Research is not registered with the United States Securities and Exchange Commission (the “SEC”): as a “broker-dealer” under the Exchange Act, as an “investment adviser” under the Investment Advisers Act of 1940, or in any other capacity. Freedom Financial Research, its owners, directors, and employees are also not registered with any state securities commission or authority as a broker-dealer or investment advisor or in any other capacity.
DISCLAIMER: Freedom Financial Research, LLC (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Light AI Inc. made a one-time payment of fifty-five thousand USD to provide marketing services for a term of one week This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing ,including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures. It is our policy that information contained in this profile was provided by the company, extracted from SEDAR+ and SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.
Freedom Financial Research and its directors, employees, and members of their households do not own any shares of Light AI Inc. (OHCFF.USOTC). However, Freedom Financial Research is extremely biased since this is a sponsored editorial.
HIGH RISK: The securities issued by the companies we feature should be seen as high risk; if you choose to invest, despite these warnings, you may lose your entire investment. You must be aware of the risks and be willing to accept them in order to invest in financial instruments, including stocks, options, and futures.
NOT PROFESSIONAL ADVICE: By reading this, you agree to all of the following: You understand this to be an expression of opinions and NOT professional advice. You are solely responsible for the use of any content and hold Freedom Financial Research and all partners, members, and affiliates harmless in any event or claim. While Freedom Financial Research strives to provide accurate and reliable information sourced from believed-to-be trustworthy sources, we cannot guarantee the accuracy or reliability of the information. The information provided reflects conditions as they are at the moment of writing and not at any future date. Freedom Financial Research is not obligated to update, correct, or revise the information post-publication.
FORWARD-LOOKING STATEMENTS: This article contains forward-looking statements about Light AI Inc., which are identified by terms such as "anticipate," "expect," and "project." These statements reflect current views regarding company performance, business goals, healthcare market expectations, and intellectual property development. The statements are based on current business and market expectations. However, they involve various risks and uncertainties, including potential delays, financial difficulties, operational challenges, and problems protecting intellectual property. Additional risks include possible regulatory approval delays, market disruptions, personnel issues, and competitive pressures. Given these risks and uncertainties, actual results may differ significantly from what is described in the forward-looking statements. Readers should not place undue reliance on these statements, which are only valid as of the article's publication date and we undertake no obligation to update.